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Abstract
Background: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in
all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard
therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test
EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible
amount of tissue material.
The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations
from formalin-fixed paraffin-embedded samples.
The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™
System.
Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue
sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in
the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen
del Rocío de Sevilla).
Results: The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator
test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22%
and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%.
Conclusions: The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.
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Background
Non-small-cell lung carcinoma (NSCLC) is one of the
most common cancers worldwide, contributing for
13% of all cancer types [1]. NSCLC represent the 85%
of lung cancer, mainly subdivided into two types:
squamous cell carcinoma (SCC) and non-squamous
cell carcinoma (non-SCC) of which histologically
adenocarcinoma (ADC) is the most prevalent one
(50%) [2, 3].
Mutations in the EGFR gene are commonly observed
in NSCLC particularly in ADC [4]. The gene encodes a
transmembrane glycoprotein, EGFR or HER1/ErbB1,
member of the epidermal growth factor tyrosine kinase
(TK) receptors’ family ERbB. Binding of EGFR to its li-
gands causes dimerization and tyrosine autophosphoryl-
ation. Downstream cascade activation of pathways,
results in cellular proliferation and survival [5, 6]. EGFR
gene mutations, increased gene copy number and over-
expression of EGFR proteins can however lead to consti-
tutive TK activity and carcinogenesis [7].
EGFR mutations are present in around 15% of NSCLC
[8]. EGFR mutation testing for activating “hot-spot” mu-
tations in exons 18–21 is recommended in all patients
with advanced NSCLC of the non-SCC subtype [9].
Exon 19 deletions, exon 21 (L858R, L861Q), and exon
18 (G719X) mutations are associated with sensitivity to
EGFR-tyrosine kinase inhibitors (TKIs) [10–12] where
exon 21 L858R point mutation and exon 19 deletions
are the most frequent alterations (overall 85–90%) [13].
Exon 20 (S768I) confers a good outcome to first gener-
ation EGFR TKIs (erlotinib, gefitinib), although its asso-
ciation with sensitivity or resistance to TKIs is still not
known [14]. Exon 20 insertions may predict resistance
to TKIs. Moreover, EGFR T790M mutation is one of the
main causes of acquired resistance to TKI therapy and
has been reported in about 55% of patients with disease
progression after initial response to 1st or 2nd gener-
ation TKIs [10, 11]. C797S is a second acquired resist-
ance mutation, arising in tumors that have progressed
after (osimertinib) treatment for T790M+ disease.
Nevertheless, this mutation is unusual and not currently
treatable [15].
Various commercial assays are used in routine prac-
tice to test the presence of EGFR mutations in a tu-
moral context and the majority of those have been
optimized to be compatible with DNA extracted from
formalin-fixed paraffin-embedded (FFPE) samples (ob-
tained from diagnostic biopsies, surgical resections
and even cytological specimens). Each assay is charac-
terized by a specific range of covered mutations, dif-
ferent level of automation and multiplexing, variable
cost, high turnaround time plus the need for special-
ized equipment and highly skilled staff but most of
all, each of them is characterized by specific
sensitivity, specificity and Limit of Detection (LOD)
for each one of the tested mutations.
The Idylla™ EGFR Mutation Test, as the Idylla™ KRAS
and BRAF Mutation Tests, is a fully-automated real-
time-PCR-based test designed for the detection of EGFR
mutations in a quick turnaround time (approx. 150 min)
from FFPE sample to final result. The test is performed
directly on one FFPE tissue section, requiring no before-
hand sample preparation and DNA extraction and min-
imal hands-on time. The interpretation of results is fully
automated.
This study was conducted as a Clinical Performance
Evaluation (CPE) to evaluate the performance of the
Idylla™ EGFR Mutation Test on the Idylla™ System under
the conditions of use [16, 17], in accordance with the
quality standard EN-13612 (2003) ‘Performance evalu-
ation of in vitro diagnostic medical devices’, in order to
demonstrate the followings objectives: a) overall, positive
and negative agreement for sensitizing and resistant mu-
tations; b) positive and negative agreement at the spe-
cific genotype call level; c) positive and negative
diagnostic agreement of at least 90% of the Idylla™ EGFR
Mutation Test by comparing it to a comparator test
(Therascreen® EGFR RGQ PCR v2, Qiagen), in tumor
samples of subjects with NSCLC.
Methods
Patients and samples
Samples were recruited from four different centers
[Hospital Universitario Virgen del Rocío de Sevilla,
Spain (HUVR), Universitair Ziekenhuis Leuven,
Belgium (UZL), Complejo Hospitalario de Jaén, Spain
(CHJ) and Hospital Universitario de Bellvitge, Spain
(HUB)]. The CPE study was carried out at two sites:
UZL and HUVR (reference lab due to accreditation
under the UNE-EN ISO 15189:2013 related with this
technique). Samples used for this study were slides or
curls (slices) from archived, appropriately stored and
adequately identified FFPE tumor blocks. The initial
study cohort consisted of 290 samples (42 from UZL
and 248 from HUVR). UZL tested 42 samples with
Idylla™ EGFR Mutation test and no samples with
Therascreen V2. HUVR tested 137 samples with
Idylla™ EGFR Mutation test and 179 samples with
Therascreen V2. We excluded samples due to: a) in-
clusion criteria not met (Table 1); b) absence of valid
results for both test; c) insufficient material (compara-
tion of an initial hematoxylin with the final one). At-
tending to this, the final analysis was performed on
132 samples (Fig. 1) (Table 2).
Patients provided informed consent for investigational
purposes and the institutional ethics committees of all
these centers approved the study. Main features of the
patients are shown in Table 3.
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Once CPE study was finished, the reference lab in-
cluded 82 extra samples [from HUVR, HUB, Hospital
Universitario Mútua Terrassa, Spain (HUMT) and Facul-
tade de Medicina da Universidade de Coimbra, Portugal
(FMUC)]. After the exclusion of 29 of these samples for
the same reasons as described earlier, 53 samples were
compared for Idylla™ and comparator test (supplemen-
tary Table S1).
Five-μm thick FFPE tissue sections were prepared as
close as possible to the sections previously used to gen-
erate the reference results. Tumor content, percentage
of necrosis, presence/absence of TAR (a large variety of
organic and inorganic chemicals generated by burning
tobacco that forms a brown substance between lung
cells; it is the main cause of lung and throat cancer in
smokers.) and area were determined on a hematoxylin-
eosin (HE)-stained slide by a pathologist. Macro-
dissection was performed to achieve tumor cell content
of at least 10%.
Therascreen® EGFR RGQ PCR kit version 2 used as
reference method
Therascreen® EGFR RGQ PCR Kit (version 2) was per-
formed according to the manufacturer’s instructions.
This is an In-Vitro Diagnostic (IVD) test for the detec-
tion of 29 somatic mutations G719A/S/C in exon 18, 19
deletions in exon 19, T790M, S768I and 3 insertions in
exon 20, and L858R, L861Q in exon 21 in the EGFR
oncogene, using Scorpions® and ARMS® technologies in
real-time PCR. The Therascreen® EGFR RGQ PCR Kit
was tested on DNA samples extracted from FFPE tumor
tissue from NSCLC patients (Qiagen QIAamp® DNA
FFPE-kit), and run on a Rotor-Gene Q MDx instrument.
Idylla™ EGFR mutation test
The Idylla™ EGFR Mutation Test used in the study was
an investigational use only labeled product as the IVD
Table 1 Inclusion criteria for the Idylla™ test
Inclusion criteria
1 Male or female patients ≥18 years of age
2 Samples can be used for investigational purposes according to the
applicable laws
3 Histological confirmed primary or metastatic NSCLC with known
EGFR status (valid result with the version 2 of the comparator test)
4 For Idylla™ testing: one slice or slide with a minimum of 10% tumor
cells of the total tissue used (if this is not obtained, macro-dissection
is to be performed to reach at least 10% tumor cells in total tissue
area used)
5 FFPE blocks from the institute, which preferably had a maximum
fixation time of 48 h (routine procedure) and are preferably not older
than 5 years after the date of collection, stored at ambient conditions
Fig. 1 The sample selection process
Delgado-García et al. BMC Cancer          (2020) 20:275 Page 3 of 10
version was at that moment not yet commercially avail-
able. This was the same product as the IVD version ex-
cept for its labeling. The Idylla™ EGFR Mutation Test is
a test for the qualitative detection of 51 EGFR mutations:
exon 18 (G719A/S/C), 36 deletions in exon 19 (the set
of 36 mutations in exon 19 detected with Idylla™ fully
overlap the 19 mutations detected with Therascreen),
exon 20 (T790M, S768I), 5 insertions in exon 20 (the 2
sets of mutations are overlapping in 2 mutations
(c.2310_2311insGGT; p.D770_N771insG and c.2319_
2320insCAC; p.H773_V774insH).) and exon 21 (L858R,
L861Q) in the EGFR oncogene in FFPE human malig-
nant lung cancer tissue.
FFPE tissue sections were placed (one per sample)
directly into the cartridge of the fully automated
Idylla™ platform (Biocartis, Mechelen, Belgium)
following the manufacturer’s instructions, without re-
quiring prior manual deparaffinization or FFPE pre-
processing. With a hands-on time of less than 2 min
and a total turnaround time of 150 min, the instru-
ment covers fully integrated sample preparation (with
a combination of reagents, enzymes, heat, and high
intensity focused ultrasound (HIFU) inducing deparaf-
finization, disruption of the tissue, and lysis of the
cells) combined with PCR thermocycling (via micro-
fluidic channels in the cartridge, nucleic acids are
transported into 5 separated chambers with dried
form PCR reagents) and fluorescence detection of
target sequences, using allele specific primers. A sam-
ple processing control (SPC) is included in each run
and the presence of a mutant genotype is determined
by calculating the ΔCq (quantification cycle) between
the EGFR SPC and the EGFR mutant signal(s). All re-
quired consumables are provided in the cartridge and
the Idylla™ Console and the Idylla™ instruments are
CE marked.
Evaluation of samples and interferences
Although inclusion criteria were well established, an as-
sessment was made for different characteristics of sam-
ples to avoid invalid or false results, including:
i) Age of prepared FFPE blocks: 14 samples with an
unknown preparation date and 9 blocks older than
5 years.
ii) Macro-dissection: needed to increase the
percentage of tumor nuclei to reach at least 10%.
iii) Tissue area: tissue area of samples was between 1
and 567 mm2, since there was no minimum tissue
area requirement input for the EGFR Mutation test.
iv) Other interferences: the presence of necrotic tissue
and TAR.
Nevertheless, if an invalid result was obtained, both
tests were repeated once. Invalid results may be
caused by a variety of reasons including presence of
inhibitors in the sample, insufficient DNA, incorrect
placement of a sample in a cartridge and/or sample
volume out of range. At this point, it is important to
claim that the repetition for invalid results in Ther-
ascreen was part of the study, but it is also part of
our routine diagnostic protocol, usually modifying
DNA concentration and/or repeating extraction in
order to avoid necrosis or TAR.
Analysis of discordant results
A third method was used to further analyze some of the
samples having an Idylla™ EGFR Mutation Test result
not concordant with the result of the reference method.
Next generation sequencing (NGS) and/or Droplet
Digital™ PCR (ddPCR) were used depending on the
quantity of leftover material available (sections close to
those used for the other tests were provided).
NGS was done (with a minimum amount of 8 slices)
by a validated workflow of the Tumor Hotspot MASTR™
Plus kit (Multiplicom) on the Illumina MiSeq Dx instru-
ment. NGS and the subsequent data-analyses pipeline
was done by Histogenex (minimal total mean read depth
of 185.000, exon coverage of 500x mean read depth).
The ddPCR was performed at Biocartis. ddPCR was
done on liquefied FFPE material using commercially
available ddPCR assays (Droplet Digital™ PCR Assays
Table 2 CPE study cohort
CPE study Positive EGFR Negative EGFR Total
Sevilla 27 47 74
Jaen 6 0 6
Leuven 19 22 41
Bellvitge 11 0 11
Total 63 69 132
Table 3 Demographic and clinical characteristics of patients. *
Mean age (year) at tumor collection date
Total number (NSCLC) 132
Gender Male: 56% Female: 43% Missing: 1%
Mean age (year)* 65
Sd: 10.12 median: 65
min: 44 max: 85
Missing: 11
Tissue location Number of patients (%)
Primary 85 (64%)
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and QX200 ddPCR system, Bio-Rad Laboratories, Inc.).
These predesigned assays contain probes for the detec-
tion of both WT and all the specific mutations. Samples
were considered positive by ddPCR when the % mutant
was ≥1%, except for T790M which was considered posi-
tive when the % mutant was ≥5%.
Furthermore, it was necessary to analyze the degree of
fragmentation to see if the DNA in the discordant sam-
ples was heavily fragmented or not, which could be a
problem for a PCR based analysis method like Idylla™. A
5-plex PCR was developed and executed by Biocartis.
Samples were liquefied on the platform following a PCR
reaction for 5 housekeeping genes: β-actin (321 bp),
ABCB (213 bp), TFRC (149 bp), HPRT (105 bp) and
RNaseP (63 bp). A sample is considered fragmented
when the size of the amplicons detected with the 5-plex
PCR is smaller than the amplicons that would be needed
for the EGFR test (EGFR PCR products range from 67 to
170 bp).
Statistical analysis
Ninety-five percent two sided confidence interval based
on Wilson’s score method [18] at the dichotomous level
(“mutation detected” versus “no mutation detected”) was
used for the estimation of total, positive and negative
agreement.
Specificity and sensitivity were defined as the propor-
tion of concordant results against the sum of concordant
and discordant results (true positives / (true positives +
false negatives) and true negatives / (true negatives +
false positives). Analyses were performed in R software
3.2.5 (R Core Development Team, 2016).
Results
Comparator test and Idylla™ EGFR mutation test
In a primary analysis on dichotomous level, the invalid
runs at first testing were excluded, resulting in a total of
122 samples. After repeat testing, 10 more samples pro-
vided a valid result for Idylla™ and/or Comparator test
V2, leading to a total of 132 samples included for the
secondary analysis.
The EGFR mutational status of 132 retrospective clin-
ical FFPE samples from patients with primary or meta-
static NSCLC was tested with Idylla™ System (Idylla™),
and results were compared with the original assessments
made by Therascreen® EGFR RGQ PCR Kit (version 2).
Idylla™ results were not used for any diagnostic or thera-
peutic purposes.
We obtained 57 positive samples for EGFR mutation
and 75 wild-type cases. Idylla™ demonstrated agreement
with routine method in 121 out of 132 samples (91.7%).
Two samples had an Idylla™ result with a positive muta-
tion detected that was not detected by the Therascreen®
test. Four samples had a Therascreen® result with a
positive mutation that was not detected by the Idylla™
test. Three samples had different positive mutations de-
tected by both tests, and two samples contained a spe-
cific exon 20 insertion: c.2311_2319dupAACCCCCAC;
p.Asn771_His773dup [p.N771_H773dup] that was not
targeted by the Idylla™ EGFR Mutation Test and were
therefore discordant by design (Table 4).
Samples characteristics
The age of the FFPE blocks should be preferably
maximum 5 years after the date of collection. This
was the case for all the blocks except for 14 samples
for which the preparation date is “unknown” and 9
blocks which were older than 5 years. All samples
have been included in the analysis, since no age-
related trend regarding invalid tests was identified
(supplementary Table 2).
Tissue area of samples was between 1 and 567 mm2.
No tissue size-related trend was observed in valid and
discordant rate. The samples with a tissue area below
10mm2 still led to valid and concordant results in > 90%
of the samples (supplementary Table 3).
The influence of the presence of necrotic tissue and
TAR on the results was evaluated in all samples where
possible. Results showed that neither necrotic tissue-
related nor TAR-related trends were apparent in the ob-
tained results (supplementary Table 4).
Comparison between both methods
A valid result with both methods was obtained for 132
out 179 of initially selected samples. After the exclusion
of two discordant results by design, the agreement be-
tween Idylla™ and the comparator test was calculated
based on the dichotomous response whether a mutation
was detected or not. Table 5 shows the raw data used to
calculate it. The overall agreement (defined as the pro-
portion of concordant results in all results) for 130 sam-
ples was 95.38% with a lower limit of the 95%
confidence interval (CI) of 91.32. Positive agreement was
calculated to be 93.22% CI of 85.73, and, the negative
agreement was calculated to be 97.18% CI of 91.84
(Table 6).
Invalid results were obtained for 47 out 179 selected
samples: with Idylla™ or with comparator test or with
both technologies: invalid result only for Therascreen®
(34 out 47); invalid result only for Idylla™ (6 out 47); in-
valid result for both tests (7 out 47).
An additional post-CPE study was done with 53 extra
samples with the same characteristics described previ-
ously. Idylla™ results showed agreement with routine
method in 49 samples. We found that 3 samples had a
Therascreen® result with a positive mutation detected
that was not detected by the Idylla™ test, and 1 sample
had different positive mutations detected by the two
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tests. However, the overall concordance between the
Idylla™ EGFR Mutation Test and the reference routine
method was found to be 94.34%, with a negative agree-
ment of 100% and a positive agreement of 89.26% (sup-
plementary Tables 5, 6 and 7). Discordant results were
not analyzed.
Discordant results
Discordant samples were tested with NGS and/or
ddPCR to investigate the root-cause of the discordances.
A discordant result was observed for 11 samples
(Table 4). Two discordant results were the result of a
specific insertion (p.Asn771_His773dup) that is not tar-
geted in the design of the Idylla™ EGFR Mutation Test
(discordant by design) and were not taken into account
in the agreement calculations. Four discordant samples
had insufficient material for NGS analysis. The
remaining five discordant samples were included in NGS
analyses, together with six random concordant samples
(Table 7). All six concordant samples were confirmed
using NGS (data not shown).
Discussion
Molecular diagnosis for activating “hot-spot” mutations
in EGFR exons 18 to 21 is recommended in all patients
with advanced NSCLC of a non-SCC subtype since TKI
therapy provides significant improvement in survival and
quality of life [9].
Classical methods for testing EGFR in FFPE material
require tissue deparaffinization, manual isolation of
DNA and DNA quantification [9]. Therascreen® EGFR
RGQ PCR Kit (version 2) with a total turnaround time
of 20 h (including DNA extraction, purification and
PCR), is considered a robust method for the detection of
‘hot spot’ mutations predictive of TKI response, and is
widely utilized [19, 20].
The Idylla™ EGFR Mutation Test, performed on the
Biocartis Idylla™ System, is an in vitro diagnostic fully
automated real-time PCR based test for the qualitative
detection of EGFR mutations, from FFPE sample to final
result. The test is performed directly on one FFPE tissue
section, requiring no beforehand sample preparation and
minimal hands-on time, yielding results within 2.5 h.
This test encompasses 51 EGFR clinically relevant muta-
tions from exons 18 to 21 in human lung cancer FFPE
material (according to the latest IASLC atlas of EGFR
testing in lung cancer) [21].
The performance of the Idylla™ platform has been pre-
viously reported in various studies [16, 17, 22–25].
This CPE study compared the Therascreen® EGFR
RGQ PCR v2 to the Idylla™ EGFR Mutation Test,
showed an overall presence of EGFR mutations in the
samples of 45.38% when measured with Therascreen®
EGFR RGQ PCR v2 and of 43.85% measured with the
Idylla™ EGFR Mutation Test, demonstrating that the
sensitivity of the Idylla™ EGFR Mutation Test is compar-
able to the sensitivity of the routine reference method.
The overall concordance between the Idylla™ EGFR Mu-
tation Test and the reference routine method was found
to be 95.38% [95% CI: 91.32%-100], indicating a good
concordance, showing the near-equivalence of both
measuring techniques, and, consequently, test robustness
for Idylla™.
After the exclusion of 2 results discordant by design
(with the specific insertion p.Asn771_His773dup that is
not targeted in the design of Idylla™ EGFR Mutation
Test), 9 discordant results were found between both
methods. Using NGS and/or ddPCR and analyzing the
degree of DNA fragmentation, the main reasons of these
discrepancies were studied, including insufficient mater-
ial, low sample input and/or low allelic frequency (in the
cases with enough leftover material and good sample
quality) (Table 7).
Besides, several other pre-analytical parameters were
evaluated, such as the age of the FFPE blocks, tissue
area, percentage of necrotic tissue, and the presence of
TAR. For these 4 parameters, no correlation could be
found, indicating that the Idylla™ EGFR Mutation Test is
a robust test.
The number of invalid results, obtained with one of
the two methods or with both, represents an interesting
aspect of this study. We obtained a Therascreen® invalid
result for 34 out 47 samples. As we detailed before,
Table 6 Measures of agreement
Measure Rate Point estimate 95% lower limit (1-sided) 95% upper limit (1-sided)
Overall Diagnostic Agreement 124/130 95.38 91.32 100
Positive Diagnostic Agreement 55/59 93.22 85.73 100
Negative Diagnostic Agreement 69/71 97.18 91.84 100
Table 5 Agreement table at the dichotomous level for valid,
non-missing results
Therascreen®
Idylla™ Mutant WT Totals
Mutant 55 2 57
WT 4 69 73
Totals 59 71 130a
an = 130 samples after excluding two discordant by design
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repetitions with this test occur during our routine prac-
tice and, for those cases, we usually modify DNA con-
centration and/or repeat extraction in order to avoid
necrosis or TAR. However, although we modified the
starting material in the repetitions, this strategy was not
enough to obtain an evaluable result for these samples
tested with the comparator test.
Invalid results for Idylla™ (6 out 47 samples) were
mainly due to the absence of amplification of the in-
ternal control. We repeated the test at least one time for
each one of the invalid cases obtaining the same result.
We considered to try to avoid necrosis or TAR with
macrodissection but, as previously demonstrated, these
characteristics do not interfere with the final result.
Finally, invalid results for both test were obtained for 7
out 47 samples, and, although we repeated these samples
with both techniques once, we obtained the same result.
We argued that this kind of samples presented some in-
trinsic artefacts no controlled in our lab, for example, an
improper fixation time and/or a more elevated presence
of specific PCR inhibitors due to the process, concluding
that the quality of these samples was not adequate to
study the mutational status of the EGFR gene.
The small number of invalid samples obtained with
Idylla represents an important aspect for the EGFR sta-
tus determination because more patients could be
screened for these mutations in order to receive a more
personalized treatment.
The advantages of this system have been clearly exposed
before [16, 17, 22–25], the load of FFPE samples directly
into single use cartridges with minimal sample preparation
(and as consequence, minimal probability of contamina-
tions), a quick turnaround time and a fully automated inter-
pretation of results. Some disadvantages and/or cautions
need to be kept in mind, such as a limited throughput (due
to the system only processing one sample at a time) and,
consequently, the difficulties for laboratories with high daily
sample workload. However, is possible to add up to eight
different modular systems to the same console.
At this point, it is important to emphasize the crucial
importance of the pathologist’s pre-analytical evaluation
in assessing the percentage of tumor cells, and other
characteristics. Previous (and mandatory) evaluation of
tissue helps to avoid false and/or invalid results.
Conclusions
All the characteristics exposed before, together with the
high concordance with the reference method [Therascreen®
EGFR RGQ PCR Kit (version 2)], indicate that Idylla™ EGFR
Mutation Test on the Idylla™ System is a fully-automated
method, designed for the detection of EGFR mutations in a
quick turnaround time from FFPE sample to final result
and can be a suitable clinical test for routine use in diagnos-
tic procedures.
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